The US Food and Drug Administration (FDA) has approved STELARA for treating moderate-to-severe plaque psoriasis in children.
The US Food and Drug Administration expanded the indication for STELARA® (ustekinumab) to treat moderate-to-severe plaque psoriasis in children aged 6 to 11 years.1 The drug targets interleukin (IL)-12 and IL-23, which is key to moderating the overactive inflammatory response. The drug is given as an injection under the skin 4 times a year, following 2 starter doses.
The approval of the drug was based on the results from the CADMUS Junior study, which was an open-label, single-arm, multicenter phase 3 clinical trial. The study included 44 children who had moderate-to-severe plaque psoriasis and 77% of them had clear or almost clear skin at week 12, after receiving 2 doses. The study results showed that 84% achieved a Psoriasis Area and Severity Index (PASI) 75 response and 64% achieved a PASI 90 response.
Overall, the safety in the pediatric population was similar to the safety results seen in the adult population. Common adverse events include nasal congestion, sore throat, itching, tiredness, and headache. One potentially mitigating factor in the study was that the participants were aware that they were receiving ustekinumab.
Reference
1. Janssen Johnson. US Food and Drug Administration approves STELARA® (ustekinumab) for treatment of pediatric patients with moderate to severe plaque psoriasis. Prnewswire.com. Published July 30, 2020. Accessed July 31, 2020. https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-stelara-ustekinumab-for-treatment-of-pediatric-patien
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.